百济神州第二大单品替雷利珠单抗2025年全球销售额7.37亿美元，增长19%。替雷利珠单抗是一款针对免疫检查点受体程序性细胞死亡蛋白1（PD-1）的人源化IgG4单克隆抗体，其设计旨在最大限度地减少与Fcγ受体（FcγR）结合（FcγR被认为在激活巨噬细胞吞噬作用中发挥重要作用），并尽可能减少其对T效应细胞的负面影响。随着后续适应症拓展，全球收入规模将持续保持增长。商业化情况替雷利珠单抗已在全球...
Source Link百济神州第二大单品替雷利珠单抗2025年全球销售额7.37亿美元，增长19%。替雷利珠单抗是一款针对免疫检查点受体程序性细胞死亡蛋白1（PD-1）的人源化IgG4单克隆抗体，其设计旨在最大限度地减少与Fcγ受体（FcγR）结合（FcγR被认为在激活巨噬细胞吞噬作用中发挥重要作用），并尽可能减少其对T效应细胞的负面影响。随着后续适应症拓展，全球收入规模将持续保持增长。商业化情况替雷利珠单抗已在全球...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.